Considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prevest Denpro's board, meeting on February 14, 2026, approved unaudited Q3 FY26 (quarter ended Dec 31, 2025) standalone and consolidated results with a clean limited review report from auditor Mittal & Associates. Standalone revenue from operations rose ~23% YoY to Rs 1,837.46 lakhs (vs Rs 1,492.62 lakhs in Q3 FY25), while standalone net profit grew ~15% to Rs 515.07 lakhs (vs Rs 446.37 lakhs), with EPS of Rs 4.29. For the nine months ended Dec 2025, standalone revenue was Rs 5,276.02 lakhs and net profit Rs 1,535.45 lakhs. On a consolidated basis, Q3 net profit was Rs 472.09 lakhs (EPS Rs 3.93) and 9M net profit was Rs 1,466.91 lakhs, with subsidiary Denvisio Biomed contributing. Previous period figures were restated/regrouped for comparability.
Strong top-line growth (~23% YoY standalone) and a clean auditor opinion support a positive near-term outlook for shareholders, though consolidated PAT growth was modest (~4% YoY) reflecting limited subsidiary contribution. No material signals on debt, governance issues, or auditor changes.